Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
| ▸ | SGMS2 | Q8NHU3 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL571739 | 0.89 | HTT (0.57) | HTTALDH1A1TDP1POLBL3MBTL1 | |
| SCHEMBL1316136 | 0.87 | HPGD (0.51) | HTTALDH1A1FOLH1POLBKDM4E | |
| SCHEMBL6160019 | 0.87 | KMT2A (0.52) | ALDH1A1TDP1POLBL3MBTL1KMT2A | |
| SCHEMBL16787357 | 0.87 | TSHR (0.62) | HTTALDH1A1TDP1POLBKDM4E | |
| SCHEMBL27141664 | 0.86 | ALDH1A1 (0.50) | HTTALDH1A1TDP1POLBKDM4E | |
| SCHEMBL31656251 | 0.86 | ALDH1A1 (0.50) | HTTALDH1A1TDP1POLBKDM4E | |
| SCHEMBL23812434 | 0.85 | ALDH1A1 (0.63) | ALDH1A1TDP1POLBKDM4EL3MBTL1 | |
| SCHEMBL23809724 | 0.85 | ALDH1A1 (0.62) | HTTALDH1A1TDP1FOLH1POLB | |
| SCHEMBL1647432 | 0.84 | TDP1 (0.58) | HTTALDH1A1TDP1FOLH1POLB | |
| SCHEMBL20695025 | 0.84 | ALDH1A1 (0.57) | ALDH1A1TDP1POLBKDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190382422-A1 | SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2019-12-19 | — | — | US | disclosed |
| US-10377780-B2 | Salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2019-08-13 | — | — | US | disclosed |
| US-10377780-B2 | Salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2019-08-13 | — | — | US | disclosed |
| CN-110003104-A | Salicyclic acid derivatives, its pharmaceutically acceptable salt, its composition and its application method | 多伦多大学管理委员会 | 2019-07-12 | — | — | CN | disclosed |
| CN-105120854-B | Novel salicylic acid derivatives, pharmaceutically acceptable salts thereof, compositions thereof, and methods of use thereof | 多伦多大学管理委员会 | 2019-04-09 | — | — | CN | disclosed |
| US-20170267704-A1 | SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2017-09-21 | — | — | US | disclosed |
| US-20170267704-A1 | SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2017-09-21 | — | — | US | disclosed |
| US-20170267704-A1 | SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2017-09-21 | — | — | US | disclosed |
| US-9650399-B2 | Salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2017-05-16 | — | — | US | disclosed |
| US-9650399-B2 | Salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2017-05-16 | — | — | US | disclosed |
| US-9650399-B2 | Salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2017-05-16 | — | — | US | disclosed |
| EP-2960238-B1 | MONOCYCLIC PYRIDINE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2017-04-05 | — | — | EP | disclosed |
| EP-2960238-A1 | MONOCYCLIC PYRIDINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2015-12-30 | — | — | EP | disclosed |
| CN-105120854-A | Novel salicylic acid derivatives, pharmaceutically acceptable salts thereof, compositions thereof, and methods of use thereof | UNIV TORONTO | 2015-12-02 | — | — | CN | disclosed |
| US-20150158894-A1 | SALICYCLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | UTI LIMITED PARTNERSHIP (CA) | 2015-06-11 | — | — | US | disclosed |
| US-20150158894-A1 | SALICYCLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | UTI LIMITED PARTNERSHIP (CA) | 2015-06-11 | — | — | US | disclosed |
| US-20150158894-A1 | SALICYCLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | UTI LIMITED PARTNERSHIP (CA) | 2015-06-11 | — | — | US | disclosed |
| EP-2854819-A2 | NEW SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | The Governing Council of the University of Toronto (CA) | 2015-04-08 | — | — | EP | disclosed |
| WO-2013177534-A2 | NEW SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2013-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190382422-A1 | SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | STAT3, STAT5A, STAT6 | HTT 3988/4885ALDH1A1 722/4885TDP1 2922/4885 |
| US-20170267704-A1 | SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | STAT3, STAT5A, STAT6 | HTT 3988/4885ALDH1A1 722/4885TDP1 2922/4885 |
| US-10377780-B2 | Salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof | STAT3, STAT5A, STAT6 | HTT 3988/4885ALDH1A1 722/4885TDP1 2922/4885 |
| US-20150158894-A1 | SALICYCLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | STAT3, STAT5A, JAK2 | HTT 4065/4885ALDH1A1 836/4885TDP1 2863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.